Raymond James has hired experienced finance professional Andrew Gitkin as managing director and co-head of the firm’s Health Care Investment Banking practice. Along with Managing Director Riley Sweat, Gitkin will co-lead the firm’s health care investment banking efforts. Specifically, he will focus on the life sciences and biotechnology sector – an area in which he is deeply experienced and has served for the last 15 years of his career. He will be based in Los Angeles in the investment banking division’s newly established office.
“Andrew is a highly regarded professional with an exceptional understanding of the biotech, life sciences and health care space,” said Jim Bunn, president of Raymond James Global Equities and Investment Banking group. “He’s built an exceptional reputation in the sector and is adept at delivering results to clients, so we are thrilled to welcome him to our team and lead our efforts in this area.”
Gitkin joins Raymond James from Piper Jaffray where he led the West Coast biotech investment banking practice. Prior to Piper Jaffray, Gitkin was an investment banker with Moelis & Co. Earlier in his career, Gitkin was a health care portfolio manager at both Tavistock Life Sciences and Saddle Point Asset Management and worked in health care equity research at Salomon Smith Barney and Paine Webber/UBS and was awarded rankings by both Institutional Investor1 and Greenwich Associates2, as well as winning recognition in Crain’s Business “40 under 40” reports3.
Gitkin earned a bachelor’s degree in business administration from Emory University’s Goizueta Business School in Atlanta, Ga.
“I am very excited to join my co-head Riley Sweat and the highly successful Raymond James Health Care Investment Banking team,” said Gitkin. “Over the last few years both the bankers and the equity research analysts have established a strong reputation in the life sciences area; and Raymond James, overall, has built a powerful global banking platform that I am looking forward to leveraging on behalf of my clients and helping to grow, particularly in the important West Coast market.”
Raymond James will be hosting its inaugural Life Sciences and MedTech Conference in New York, June 18-19, 2019. Sweat and Gitkin along with the Raymond James health care/biotech equity research analysts’ team will welcome key executives from top companies in the biotechnology, pharmaceutical and medical technology sectors.
1. Institutional Investor solicits the opinions of directors of research and heads of investment at institutions with major securities holdings in the US to select the members of the All-America Research Team. Over 3,000 nominations are typically received. Sectors are organized within broad categories: Basic Materials; Capital Goods/Industrials; Consumer; Energy; Financial Institutions; Health Care; Technology, Media & Telecommunications; and Economics & Strategy. All produce complete results (first place through third). Rankings are determined strictly by using numerical scores. Analysts must be certified pursuant to Regulation AC to be recognized as winners or team leaders in all Research sectors; Voters are subject to eligibility requirements, and winners must achieve a minimum vote count. All ballots are subject to review by our Research Operations Group.
2. Between December and February each year, Greenwich Associates interviews over 200 U.S. generalist equity portfolio managers, over 100 small/mid-cap fund managers, over 300 U.S. equity traders, and approximately 70 portfolio traders at buy-side institutions. The study participants are asked to evaluate the sales, research and trading services they receive from their equity brokers and to report on important market practices and trends.
3. Crain’s 40 under 40 list is published each year in March. Nominees must demonstrate professional success, community service as well as participation in trade groups, etc. Winners must be no older than 39 on the list’s publication date, and work full time in the New York business community (five boroughs of Manhattan and Nassau, Suffolk, Westchester, Bergen, Essex, Hudson, Morris and Union counties.). Winners are selected by a panel of Crain’s editors and reporters.
The rankings/awards may not be representative of any one client’s experience, are not an endorsement, and are not indicative of future performance. Neither Raymond James nor any of its associates paid a fee in exchange for these rankings/awards. Raymond James is not affiliated with Institutional Investor, Greenwich Associates or Crain’s.
About Raymond James Investment Banking
Raymond James Investment Banking offers highly regarded capital formation and financial advisory services. Since 2015, we have participated in raising nearly $170 billion in capital for our corporate clients and completed more than 575 advisory assignments, including more than 490 M&A buy-side or sell-side advisory assignments.
About Raymond James Financial, Inc.
Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. The company has approximately 7,900 financial advisors throughout the United States, Canada and overseas. Total client assets are $816 billion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com. Raymond James & Associates, Inc., member New York Stock Exchange/SIPC.
